Australia approves Gilead's remdesivir for Covid-19 treatment
[BENGALURU] Australia has granted provisional approval to Gilead Sciences's remdesivir as the first treatment option for Covid-19 in the country, the Therapeutic Goods Administration (TGA) said on Friday.
The approval is for adults and adolescent patients with severe Covid-19 symptoms and have been hospitalised, the Australian regulator said.
Remdesivir has become the treatment of choice for many countries against severely ill Covid-19 patients after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial.
The Australian approval broadens the use of remdesivir around the world - the United States has cleared it for emergency use and the European Commission has conditionally approved the treatment.
It is also approved as a Covid-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates.
Australia has been struggling to contain a Covid-19 outbreak in the country's second most populous city and on Friday said it would halve the number of citizens allowed to return home from overseas each week.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Biden vetoes bid to repeal US labour board rule on contract, franchise workers
Economic leaders of South Korea, Japan, China say FX volatility is a risk
US automakers win extension on use of Chinese graphite in EV tax credits
US service sector contracts in April; price pressures up
Thaksin’s daughter calls central bank independence an ‘obstacle’
US jobs growth slows in April; jobless rate up to 3.9%